- Home
- NGNE vs LOKV Comparison
NGNE vs LOKV Comparison
Compare NGNE & LOKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGNE | LOKV |
|---|---|---|
| Founded | 2003 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.8M | 296.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | NGNE | LOKV |
|---|---|---|
| Price | $22.28 | $10.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $60.13 | N/A |
| AVG Volume (30 Days) | ★ 157.3K | 23.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $925,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.88 | $9.88 |
| 52 Week High | $37.27 | $11.46 |
Technical Indicators
Market Signals| Indicator | NGNE | LOKV |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 53.72 |
| Support Level | $19.44 | $10.25 |
| Resistance Level | $25.79 | $10.34 |
| Average True Range (ATR) | 2.28 | 0.00 |
| MACD | 0.24 | -0.00 |
| Stochastic Oscillator | 51.91 | 33.67 |
Price Performance
Historical ComparisonAbout NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About LOKV Live Oak Acquisition Corp. V Class A Ordinary Shares
Live Oak Acquisition Corp V is a blank check company.